US regulator issues import alert for Dabur's Silvassa plant, citing maintenance and data integrity issues. Separately, Vedanta’s four demerged businesses prepare to list on June 15, while Lenskart sees a major investor stake sale.
Read More
P&G Health Ltd. and Sanofi Consumer Healthcare India are drawing investor attention for their exceptionally high returns on capital, which exceed 80%. These companies operate with minimal debt and asset-light models, prioritizing cash re...
Read More
Global pharma giant Novartis is pivotting its Indian operations to focus on high-end medical innovations like gene and radioligand therapies. The move signals a strategic shift from traditional drug models to complex, research-led treatm...
Read More
As dengue cases rise and the infection period extends across India, pharmaceutical companies are racing to introduce vaccines. With Takeda's Qdenga and Panacea Biotec's DengiAll reaching clinical milestones, investors are watching for re...
Read More
India’s drug regulator has authorized a 50% price ceiling increase for life-saving chemotherapy agents, carboplatin and cisplatin. By invoking emergency provisions to counteract surging raw material costs, the National Pharmaceutical Pri...
Read More
Dabur India has been hit with a US FDA Import Alert 66-40, triggering a detention of products from its Silvassa facility over data integrity and maintenance failures. While the company insists the financial impact is minimal and private-...
Read More
Cipla has received a 'Voluntary Action Indicated' (VAI) classification from the USFDA for its Goa manufacturing facility. This outcome clears a key uncertainty for investors, signaling that the regulator has found no major compliance iss...
Read More
Kiran Mazumdar-Shaw has highlighted a structural funding gap in India's biotech sector, specifically the lack of 'patient capital' for pre-revenue companies. This constraint limits the ability of early-stage firms to scale compared to gl...
Read More
India has launched the ₹10,000 crore 'Biopharma Shakti Mission' to develop 100 biologics by 2047. This initiative marks a strategic shift from generic medicine manufacturing to complex, high-value biologic drugs, which could improve prof...
Read More
The increasing prevalence of heart disease among India's younger population is driving a structural shift in the healthcare sector. As demand for preventive diagnostics, specialized cardiac care, and insurance coverage rises, investors a...
Read More
Ahmedabad-based Corona Remedies is posting strong growth by acquiring older, neglected pharmaceutical brands from giants like Dr. Reddy's and Sanofi. By focusing on established names like Wokadine and Myoril, the company achieved a 17.3%...
Read More
Glenmark Pharmaceuticals has launched Winlevi, a novel acne treatment cream, across several European markets. This marks the company's first launch of a 'New Chemical Entity' (a newly researched medicine) in Europe, signaling a strategic...
Read More
AstraZeneca Pharma India has received regulatory approval to market its cancer drug, Enhertu, as a primary treatment for HER2-positive breast cancer. This expansion into first-line treatment is a strategic move for the company’s oncology...
Read More
Healthcare stocks including Apollo Hospitals, Aster DM Healthcare, and Sai Life Sciences have reached record highs in FY27. The rally reflects strong domestic demand and sector resilience, but investors should differentiate between the h...
Read More